KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Net Margin (2016 - 2026)

TherapeuticsMD filings provide 16 years of Net Margin readings, the most recent being 1.1% for Q1 2026.

  • On a quarterly basis, Net Margin rose 322.0% to 1.1% in Q1 2026 year-over-year; TTM through Mar 2026 was 2.77%, a 66.0% increase, with the full-year FY2025 number at 2.78%, down 466.0% from a year prior.
  • Net Margin hit 1.1% in Q1 2026 for TherapeuticsMD, down from 0.78% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 36538.51% in Q2 2022 to a low of 4481.44% in Q1 2022.
  • Median Net Margin over the past 5 years was 0.94% (2025), compared with a mean of 1514.39%.
  • The widest YoY moves for Net Margin: up 3672394bps in 2022, down -428320bps in 2022.
  • TherapeuticsMD's Net Margin stood at 42.66% in 2022, then skyrocketed by 207bps to 131.08% in 2023, then plummeted by -84bps to 20.69% in 2024, then crashed by -104bps to 0.78% in 2025, then plummeted by -41bps to 1.1% in 2026.
  • The last three reported values for Net Margin were 1.1% (Q1 2026), 0.78% (Q4 2025), and 13.01% (Q3 2025) per Business Quant data.